Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 301 AL 315

Two galantamine titration regimens in patients switched from donepezil

Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N.

Acta Neurol Scand. 2012 Jul;126(1):37-44. doi: 10.1111/j.1600-0404.2011.01594.x. Epub 2011 Oct 13.

Elevation of glutathione as a therapeutic strategy in Alzheimer disease

Pocernich CB, Butterfield DA.

Biochim Biophys Acta. 2012 May;1822(5):625-30. doi: 10.1016/j.bbadis.2011.10.003. Epub 2011 Oct 12.

Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease

Mecocci P, Polidori MC.

Biochim Biophys Acta. 2012 May;1822(5):631-8. doi: 10.1016/j.bbadis.2011.10.006. Epub 2011 Oct 13.

Nanotherapeutics for Alzheimer's disease (AD): Past, present and future

Fazil M, Shadab, Baboota S, Sahni JK, Ali J.

J Drug Target. 2012 Feb;20(2):97-113. doi: 10.3109/1061186X.2011.607499. Epub 2011 Oct 25.

Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics

Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M.

Biochim Biophys Acta. 2012 May;1822(5):639-49. doi: 10.1016/j.bbadis.2011.10.011. Epub 2011 Oct 19.

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

Geerts H.

Expert Opin Investig Drugs. 2012 Jan;21(1):59-65. doi: 10.1517/13543784.2012.633510. Epub 2011 Nov 3.

Amelioration of amyloid β-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease

Majlessi N, Choopani S, Kamalinejad M, Azizi Z.

CNS Neurosci Ther. 2012 Apr;18(4):295-301. doi: 10.1111/j.1755-5949.2011.00237.x. Epub 2011 Feb 16.

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial

Ihl R, Tribanek M, Bachinskaya N; GOTADAY Study Group.

Pharmacopsychiatry. 2012 Mar;45(2):41-6. doi: 10.1055/s-0031-1291217. Epub 2011 Nov 15.

γ-Secretase inhibitors and modulators for Alzheimer's disease

Wolfe MS.

J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):89-98. doi: 10.1111/j.1471-4159.2011.07501.x. Epub 2011 Nov 28.

Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?

Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ.

J Neurochem. 2012 Jan;120 Suppl 1:167-185. doi: 10.1111/j.1471-4159.2011.07510.x. Epub 2011 Nov 28.

Regulation of β-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer's disease

Sun X, Bromley-Brits K, Song W.

J Neurochem. 2012 Jan;120 Suppl 1:62-70. doi: 10.1111/j.1471-4159.2011.07515.x. Epub 2011 Nov 28.

Developing β-secretase inhibitors for treatment of Alzheimer's disease

Ghosh AK, Brindisi M, Tang J.

J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):71-83. doi: 10.1111/j.1471-4159.2011.07476.x. Epub 2011 Nov 28.

Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease

Choi DY, Lee YJ, Hong JT, Lee HJ.

Brain Res Bull. 2012 Feb 10;87(2-3):144-53. doi: 10.1016/j.brainresbull.2011.11.014. Epub 2011 Nov 28.

Characterization of oral disintegrating film containing donepezil for Alzheimer disease

Liew KB, Tan YT, Peh KK.

AAPS PharmSciTech. 2012 Mar;13(1):134-42. doi: 10.1208/s12249-011-9729-4. Epub 2011 Dec 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias